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Evaluate the mortality associated with adding vasopressin 
to both low-dose and high-dose vasopressors in patients 





 Uncontrolled, generalized, intravascular inflammatory 
response to infection
 Most common cause of death in intensive care units (ICUs)1
 Increasing incidence over the last 10 years
 In-hospital mortality rate of greater than 40%2
 Most expensive condition to treat in 2013: $24 billion in annual costs3
 Treatment: 
 Fluid resuscitation (30 ml/kg) 
 Prompt administration of broad-spectrum antimicrobial agents 
 Vasoactive medications
Surviving Sepsis Guidelines
 Norepinephrine recommended as first-choice vasopressor 
(strong recommendation, moderate quality of evidence) 
 Suggest adding either vasopressin (weak recommendation, low 
quality of evidence) or epinephrine (weak recommendation, 
low quality of evidence) 
 Raise MAP to target (recommended target of 65 mmHg) 
 Decrease norepinephrine requirements
5
Vasopressin mechanism 
 Distinct mechanism compared to catecholamine agents
 Activates V1 receptors
 Induces constriction of vascular smooth muscle cells through 
increased intra-cellular calcium and decreased nitric oxide induced 
vasodilation
 Endogenous levels initially increase in response to hypotension 
but quickly decline within 36 hours




 Multi-center, randomized, double-blind trial
 Patients receiving norepinephrine at a minimum rate of 5 mcg/minute 
were randomly divided into two groups: 
 Low-dose vasopressin (in addition to open-label vasopressors)
 Norepinephrine (in addition to open-label vasopressors)
 Primary outcome: 28-day mortality after the initiation of study infusion 
 Sub-group analysis that divided patients into additional two groups:
 Less severe shock: Norepinephrine rate 5-14 mcg/minute at randomization
 More severe shock : Norepinephrine rate ≥15 mcg/minute at randomization







Time to study drug infusion - hours 11.5 + 9.4 11.9 + 8.9 0.57
28-day mortality – no (%) 150 (39.3) 140 (35.4) 0.26
90-day mortality – no (%) 188 (49.6) 172 (43.9) 0.11
More severe shock – NE ≥ 15 mcg/minute
28-day mortality – no/total no (%) 85/200 (42.5) 88/200 (44.0) 0.76
90-day mortality – no/total no (%) 105/199 (52.8) 103/199 (51.8) 0.84
Less severe shock – NE 5-14 mcg/minute
28-day mortality – no/total no (%) 65/182 (35.7) 52/196 (26.5) 0.05
90-day mortality – no/total no (%) 83/180 (46.1) 69/193 (35.8) 0.04
VANISH trial 
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 Factorial, double-blind, randomized trial 
 Four groups: 
 Vasopressin and hydrocortisone 
 Vasopressin and placebo 
 Norepinephrine and hydrocortisone 
 Norepinephrine and placebo 
 Primary outcome: Kidney failure-free days 28-days post 
randomization 
VANISH trial results 
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Time to study drug infusion 
- hours
3.2 (1.8-5) 3.5 (2.5-5.4) 3.7 (1.7-5) 3.5 (1.4-5.4)
28-day mortality – no/total 
no (%)
33/100 (33.0) 30/104 (28.8) 29/101 (28.7) 27/103 (26.2)
ICU mortality – no/total no 
(%)
32/100 (32.0) 26/104 (25.0) 24/101 (23.8) 27/103 (26.2)
Hospital mortality –
no/total no (%)
35/100 (35.0) 33/104 (31.7) 31/101 (30.7) 29/103 (28.2) 
Time to shock reversal -
hours







Vasopressin initiation within 
6 hours of shock onset vs. 
vasopressin within 6-48 
hours of shock onset
 Early vasopressin resulted in significantly less new-onset 
arrhythmias
 No difference in duration of catecholamine and 
vasopressin therapy 





Early addition of vasopressin 
within 4 hours of septic 
shock onset vs. 
norepinephrine 
monotherapy
 Significantly shorter time to MAP target (7.6 vs. 5.7 hours; 
p=0.058)
 No difference in mortality, norepinephrine duration, 
vasopressin duration, or ICU/hospital length of stay
Hammond et al.11
Single-center, retrospective, cohort 
study
N=96
Early addition of vasopressin 
within 4 hours of septic 
shock onset vs. 
norepinephrine 
monotherapy 
 Significantly shorter time to MAP target and hospital 
length of stay but no difference in ICU length of stay
 Significantly greater reduction in SOFA score at 72 hours 
post shock onset 
 No difference in SOFA score at 6, 24, or 72 hours post 
shock onset
 No difference in in-hospital or 28-day mortality 
 No difference in norepinephrine duration
Wu et al.12
Single-center, retrospective, cohort 
study 
N=148
Vasopressin initiation for 
patients requiring ≥10 
mcg/min of norepinephrine 
vs. patients requiring ≥50 
mcg/min of norepinephrine
 No difference in time to MAP target, mortality, or 
ICU/hospital length of stay
Study rationale
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Conflicting evidence and lack of recommendations regarding: 
 Optimal candidates for vasopressin
 Optimal timing of vasopressin initiation 
 Optimal timing of vasopressin discontinuation 
High relative cost of vasopressin compared to other 
vasopressors prioritizes its optimization 
Purpose
To evaluate outcomes for patients with septic shock based on 
the utilization of vasopressin
Research questions: 
 Does the addition of vasopressin to low-dose vasopressors in 
patients with septic shock reduce in-hospital mortality?
 Does the addition of vasopressin to high-dose vasopressors in 
patients with septic shock reduce in-hospital mortality?
13
Design
Design: IRB-exempt, retrospective chart review of patients treated with 
vasopressors and diagnosed with septic shock
Time frame: January 1, 2018 to September 17, 2018
Setting: Intensive care unit (ICU) at Baptist Hospital of Miami 





• ≥ 18 years old




• “Cardiogenic shock” documented in the medical record
• Post-cardiothoracic surgery 
• <12 hours on vasopressors
Comparator groups
• Patients treated with vasopressin
• Patients treated without vasopressin
Low-dose vasopressors: 
≤ 0.2 mcg/kg/minute NE equivalents
• Patients treated with vasopressin 
• Patients treated without vasopressin
High-dose vasopressors:




 In-hospital mortality from any cause or initiation of hospice 
care 
Secondary outcomes: 
 Total time on vasopressors (hours) 
 Number of catecholamine agents required
 ICU length of stay (days) 






















 <18 years old
 <12 hours on vasopressors 
 No septic shock diagnosis
 Post-cardiothoracic surgery
 Cardiogenic shock diagnosis
 No vasopressors initiated
Septic shock accounted for 
~38% of vasopressin 
utilization over this time 
period
Results: Low-dose arm 
19
Baseline characteristics: Low-dose arm
20





Age - years 70.7 + 13.7 63.7 + 18.7 0.12
Male sex – no (%) 23 (65.7) 11 (55) 0.43
APACHE II score 18.1 + 5.8 18.1 + 7.0 1.00
SOFA score 5.1 + 2.2 5.6 + 2.6 0.45
Lactic acid – mg/dL 3.0 + 1.9 3.2 + 2.6 0.74
MAP – mmHg 65.3 + 12.0 63.7 + 8.8 0.60
NE-equivalent dose – mcg/kg/min 10.4 + 5.4 10.6 + 7.8 0.91
All baseline characteristics at time of vasopressor initiation
All values displayed as mean + standard deviation unless otherwise noted
NE-equivalent dose equation from VASST trial 








In-hospital mortality – no (%) 7 (20.0) 7 (35.0) 0.22





Mean time on vasopressors - hours 52.6 + 56.3 75.5 + 40.2 0.12
Mean time on vasopressors for patients 
surviving to discharge - hours
45.3 + 38.4 66.9 + 41.2 0.06
Mean ICU length of stay - days 3.6 + 2.8 10.1 + 9.0 0.0002
Mean hospital length of stay - days 12.8 + 12.5 30.6 + 27.4 0.001
Number of catecholamines at time of 
inclusion
One agent: 35 (100) No other agents: 4 (20)
One agent: 14 (70)
Two agents: 2 (10)
Maximum number of catecholamines 
following inclusion 
One agent: 34 (97)
Two agents: 1 (3)
One agent: 10 (50)
Two agents: 9 (45)
Three agents: 1 (5)






Steroids administered – no (%) 17 (49) 9 (45)
Midodrine administered – no (%)
Average norepinephrine rate of 2.6 mcg/min at 
initiation
9 (26) 2 (10)
Mean time to vasopressin administration - hours (range) 10.8 (0-45.3)
Mean duration of vasopressin – hours (range) 40.7 (12.3-90.8)
Results: High-dose arm 
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Baseline characteristics: High-dose arm
24





Age - years 75.8 + 10.8 73.2 + 14.2 0.18
Male sex – no (%) 32 (69.6) 27 (56.3) 0.16
APACHE II score 21.2 + 6.0 22.6 + 6.5 0.28
SOFA score 6.0 + 2.3 6.5 + 3.1 0.38
Lactic acid – mg/dL 3.1 + 1.9 4.7 + 4.6 0.03
MAP – mmHg 67.1 + 15.5 66.8 + 15.3 0.93
NE-equivalent dose – mcg/kg/min 42.4 + 49.2 58.2 + 53.3 0.14
All baseline characteristics at time of vasopressor initiation
All values displayed as mean + standard deviation unless otherwise noted
NE-equivalent dose equation from VASST trial 







In-hospital mortality – no (%) 20 (43.5) 34 (70.8) 0.007









Mean time on vasopressors for patients 















Number of catecholamines at time of 
inclusion
One agent: 35 (76) 
Two agents: 11 (24)
One agent: 35 (73)
Two agents: 13 (27)
Maximum number of catecholamines 
following inclusion 
One agent: 37 (72)
Two agents: 13 (28)
One agent: 22 (46)
Two agents: 21 (44)
Three agents: 4 (8)
Four agents: 1 (2)






Steroids administered – no (%) 21 (45.7) 25 (52.1)
Midodrine administered – no (%) 20 (43.5) 19 (39.6)
Mean time to vasopressin administration - hours (range)
24.7 (0-177.3)
Mean duration of vasopressin – hours (range)
62.4 (1.8-403)
Limitations
 Higher vasopressin dose utilized than recommended by the 
Surviving Sepsis Guidelines
 Small sample size in low-dose vasopressor with vasopressin group 
(n=20)
 Potential for inaccurate charting of vasopressor initiation, rate 
change, and discontinuation
 Potential for inaccurate reporting of septic shock diagnosis in 
electronic medical record
 Unknown administration of fluid resuscitation prior to initiation of 
vasopressors
 Additional causes of mortality not accounted for 
 Evaluated in-hospital mortality with unknown extended outcomes
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Conclusions
 No in-hospital mortality benefit associated with vasopressin 
utilization in both the low- and high-dose arms
 No difference in duration of vasopressor therapy associated 
with vasopressin administration in both the low- and high-
dose arms 
 Opportunity for optimization of vasopressin utilization based 
on poor associated outcomes 
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Self-assessment question
 Which of the following is an outcome of the VASST trial? 
A. 28-day mortality benefit seen with initiation of vasopressin prior to 
norepinephrine 
B. Increased 28-day mortality for patients administered vasopressin 
C. Significantly more days free of organ dysfunction for patients 
administered vasopressin




 Which of the following is an outcome of the VASST trial? 
A. 28-day mortality benefit seen with initiation of vasopressin prior to 
norepinephrine 
B. Increased 28-day mortality for patients administered vasopressin 
C. Significantly more days free of organ dysfunction for patients 
administered vasopressin




1. Kadri SS, Rhee C, Strich JR, et al. Estimating ten-year trends in septic shock incidence and mortality in the United States Academic  Medical Centers using 
clinical data. Chest. 2017;151:278-85. 
2. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801-10.
3. Torio CM, Moore BJ. National Inpatient Hospital Costs: The most expensive conditions by payer, 2013. Rockville MD: Agency for Healthcare Research and 
Quality. May 2016. 
4. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997;95:1122-1125. 
5. Marsh JD, Margolis TI, Kim D. Mechanism of diminished contractile response to catecholamines during acidosis. Am J Physiol. 1988;254(1, pt 2):H20-H27. 
6. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 
2017;45:486-552. 
7. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358:877-887.
8. Gordon AC, Mason AJ, Thirunavukkarasu N, et al; VANISH Investigators. Effect of early vasopressin vs norepinephrine on kidney failure in patients with 
septic shock: the VANISH ran- domized clinical trial. JAMA. 2016;316:509-518. 
9. Reardon DP, DeGrado JR, Anger KE, Szumita PM. Early vasopressin reduces incidence of new onset arrhythmias. J Crit Care. 2014;29:482-485. 
10. Hammond DA, Ficek OA, Painter JT, et al. Prospective open-label trial of early concomitant vasopressin and nor- epinephrine therapy versus initial 
norepinephrine monother- apy in septic shock. Pharmacotherapy. 2018;38:531-538. 
11. Hammond DA, Cullen J, Painter JT, et al. Efficacy and safety of the early addition of vasopressin to norepinephrine in septic shock. J Intensive Care Med. 
2019;34:910-916. 
12. Wu JY, Stollings JL, Wheeler AP, Semler MW, Rice TW. Efficacy and outcomes after vasopressin guideline implemen- tation in septic shock. Ann 
Pharmacother. 2017;51:13-20. 
13. Gordon AC, Mason AJ, Perkins GD, et al. The interaction of vasopressin and corticosteroids in septic shock. Critical Care Medicine. 2014;42:1325-1333.
14. Der-Nigoghossian C, Hammond DA, Ammar MA. Narrative review of controversies involving vasopressin use in septic shock and practical considerations. 
Ann Pharmacother. 2020;0:1-9. 
31
Acknowledgements 
 Heidi Clarke, PharmD, BCCCP
 Jonathan Kline, PharmD, BCCCP
 Payal Patel, PharmD, BCCCP
32
Evaluating the association between 
vasopressin use and in-hospital 
mortality in patients with septic shock 
33
Michael Pasqualicchio, PharmD, BCPS
PGY-2 Critical Care Pharmacy Resident
Baptist Hospital of Miami
Michaelpa@baptisthealth.net
